AstraZeneca to acquire Amolyt Pharma
2024-03-14
临床1期并购临床3期
AstraZeneca will acquire Amolyt Pharma, a clinical-stage biotech company specializing in the development of treatments for rare endocrine disorders.
The move, executed through Alexion, AstraZeneca Rare Disease, will further strengthen the drugmaker's late-stage pipeline in rare endocrine disease through the acquisition of eneboparatide (AZP-3601), a phase 3 therapeutic peptide. Eneboparatide, designed to treat hypoparathyroidism, binds selectively to the parathyroid hormone receptor, regulates serum calcium levels, reduce urinary calcium excretion, and potentially prevent kidney function decline and chronic kidney disease.
Amolyt's pipeline also includes AZP-3813, a phase 1 peptide growth hormone receptor antagonistgrowth hormone receptor antagonist for the potential treatment of acromegaly, a disorder that occurs when the body makes too much growth hormone.
AstraZeneca will acquire all outstanding shares of France-based Amolyt for up to $1.05 billion, including an $800 million upfront payment and an additional $250 million contingent upon regulatory milestones. The transaction, pending customary closing conditions and regulatory approvals, is slated for completion by the end of the third quarter of 2024.
Since the creation of its Rare Disease unit following the $39 billion takeover of Alexion Pharmaceuticals in 2021, AstraZeneca has continued to snatch up rare disease drugmakers, picking up New Jersey-based Caelum Biosciences in September 2021 and Massachusetts-based LogicBio Therapeutics in October 2022.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。